341 related articles for article (PubMed ID: 27334100)
21. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
26. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
[TBL] [Abstract][Full Text] [Related]
27. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
Martin A; Lavoie L; Goetghebeur M; Schellenberg R
Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes.
Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O
Allergy Asthma Clin Immunol; 2022 Dec; 18(1):110. PubMed ID: 36566213
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.
Nicolay U; Kiessling P; Berger M; Gupta S; Yel L; Roifman CM; Gardulf A; Eichmann F; Haag S; Massion C; Ochs HD
J Clin Immunol; 2006 Jan; 26(1):65-72. PubMed ID: 16418804
[TBL] [Abstract][Full Text] [Related]
30. Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.
Sultan S; Rondeau É; Levasseur MC; Dicaire R; Decaluwe H; Haddad É
J Clin Immunol; 2017 Jul; 37(5):496-504. PubMed ID: 28597145
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin replacement treatment by rapid subcutaneous infusion.
Gaspar J; Gerritsen B; Jones A
Arch Dis Child; 1998 Jul; 79(1):48-51. PubMed ID: 9771252
[TBL] [Abstract][Full Text] [Related]
32. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
33. Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding.
Morgan C; Jolles S; Ponsford MJ; Evans K; Carne E
Curr Opin Allergy Clin Immunol; 2022 Dec; 22(6):371-379. PubMed ID: 36165464
[TBL] [Abstract][Full Text] [Related]
34. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
35. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
36. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
Shapiro R
Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
[TBL] [Abstract][Full Text] [Related]
38. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
Haddad É; Barnes D; Kafal A
Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
[TBL] [Abstract][Full Text] [Related]
39. Update on the treatment of primary immunodeficiencies.
García JM; Español T; Gurbindo MD; Casas C C
Allergol Immunopathol (Madr); 2007; 35(5):184-92. PubMed ID: 17923072
[TBL] [Abstract][Full Text] [Related]
40. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
